Daratumumab treatment shows promise for high-risk smoldering multiple myeloma in phase 3 trial Post author: Post published: December 10, 2024 Post category:uncategorized A new treatment is showing promise for people with high-risk smoldering multiple myeloma (SMM). You Might Also Like Hands-on device training improves pediatric resident communication skills October 22, 2026 Are individuals with advanced breast cancer more likely to have cardiovascular disease? January 7, 2025 Researchers urge mental health inclusion in extreme heat planning May 29, 2025
Are individuals with advanced breast cancer more likely to have cardiovascular disease? January 7, 2025